Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Grönberg, Alvar ^a   Zettergren, Louise ^a   Bergh, Kerstin ^a   Ståhle, Mona ^a,b   Heilborn, Johan ^b   Ängeby, Kristian ^a,b   Small, Pamela L ^c   Akuffo, Hannah ^a   Britton, Sven ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BACTERIAL TOXIN; DEFEROXAMINE; HYDROGEN PEROXIDE; IRON; MYCOLACTONE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TEMPOL; TIRON; TROLOX C; UNCLASSIFIED DRUG; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID; CATALASE; CHROMAN DERIVATIVE; OXIDIZING AGENT; SIDEROPHORE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL COUNT; CELL GROWTH; CELL LABELING; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FENTON REACTION; HUMAN; HUMAN CELL; IRON CHELATION; KERATINOCYTE; MYCOBACTERIUM ULCERANS; OXIDATIVE STRESS; WOUND HEALING; ADULT; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; ISOLATION AND PURIFICATION; METABOLISM; TIME;

MYCOBACTERIUM ULCERANS;

1,2-DIHYDROXYBENZENE-3,5-DISULFONIC ACID DISODIUM SALT; ADULT; ANTIOXIDANTS; BACTERIAL TOXINS; CATALASE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHROMANS; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; KERATINOCYTES; MYCOBACTERIUM ULCERANS; OXIDANTS; REACTIVE OXYGEN SPECIES; SIDEROPHORES; TIME FACTORS;

EID: 78149475337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013839     Document Type: Article

References (61)

1. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
2. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25: 447-454.
3. Mve-Obiang A, Lee RE, Portaels F, Small PL (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774-783.
4. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 1295-1304.
5. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
6. Dobos KM, Small PL, Deslauriers M, Quinn FD, King CH (2001) Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun 69: 7182-7186.
7. Navarro-Antolin J, Hernandez-Perera O, Lopez-Ongil S, Rodriguez-Puyol M, Rodriguez-Puyol D, et al. (1998) CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1. Kidney Int Suppl 68: S20-24.
8. Karbowski M, Kurono C, Wozniak M, Ostrowski M, Teranishi M, et al. (1999) Free radical-induced megamitochondria formation and apoptosis. Free Radic Biol Med 26: 396-409.
9. Ray RS, Mehrotra S, Shankar U, Babu GS, Joshi PC, et al. (2001) Evaluation of UV-induced superoxide radical generation potential of some common antibiotics. Drug Chem Toxicol 24: 191-200.
10. Hong F, Lee J, Song JW, Lee SJ, Ahn H, et al. (2002) Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidylprolyl- cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. Faseb J 16: 1633-1635.
11. Gil J, Almeida S, Oliveira CR, Rego AC (2003) Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free Radic Biol Med 35: 1500-1514.
12. Zhou X, Yang G, Davis CA, Doi SQ, Hirszel P, et al. (2004) Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney Int 65: 139-147.
13. Han SY, Chang EJ, Choi HJ, Kwak CS, Suh SI, et al. (2006) Effect of tacrolimus on the production of oxygen free radicals in hepatic mitochondria. Transplant Proc 38: 2242-2243.
14. Choi SJ, You HS, Chung SY (2008) Tacrolimus-induced apoptotic signal transduction pathway. Transplant Proc 40: 2734-2736.
15. Choi SJ, You HS, Chung SY (2008) Rapamycin-induced cytotoxic signal transduction pathway. Transplant Proc 40: 2737-2739.
16. Han YH, Kim SH, Kim SZ, Park WH (2008) Antimycin A as a mitochondria damage agent induces an S phase arrest of the cell cycle in HeLa cells. Life Sci 83: 346-355.
17. George KM, Barker LP, Welty DM, Small PL (1998) Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun 66: 587-593.
18. Bozzo C, Tiberio R, Graziola F, Pertusi G, Valente G, et al. A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells. Microbes Infect 2010 Aug 25. [Epub ahead of print].
19. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, et al. Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis 4: e577.
20. Tunon MJ, Sanchez-Campos S, Gutierrez B, Culebras JM, Gonzalez-Gallego J (2003) Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol 66: 439-445.
21. Park WH, Han YW, Kim SH, Kim SZ (2007) An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J Cell Biochem 102: 98-109.
22. Han YH, Kim SH, Kim SZ, Park WH (2008) Antimycin A as a mitochondrial electron transport inhibitor prevents the growth of human lung cancer A549 cells. Oncol Rep 20: 689-693.
23. Piskernik C, Haindl S, Behling T, Gerald Z, Kehrer I, et al. (2008) Antimycin A and lipopolysaccharide cause the leakage of superoxide radicals from rat liver mitochondria. Biochim Biophys Acta 1782: 280-285.
24. Hong H, Stinear T, Porter J, Demangel C, Leadlay PF (2007) A novel mycolactone toxin obtained by biosynthetic engineering. Chembiochem 8: 2043-2047.
25. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, et al. (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163: 3928-3935.
26. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, et al. (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204: 1395-1403.
27. Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, et al. (2001) Immune response to infection with Mycobacterium ulcerans. Infect Immun 69: 1704-1707.
28. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM (2002) Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70: 5562-5567.
29. Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD (2003) Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36: 1076-1077.
30. Phillips R, Horsfield C, Kuijper S, Sarfo SF, Obeng-Baah J, et al. (2006) Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol 13: 253-257.
31. Prevot G, Marsollier L, Carbonelle B, Pradinaud R, Coupie P, et al. (2004) [Diagnosis of Mycobacterium ulcerans infections in French Guiana]. Presse Med 33: 1516.
32. Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, et al. (2005) Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 12: 125-129.
33. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori- Adjei D, et al. (2006) Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79: 1150-1156.
34. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R (2006) T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci U S A 103: 12831-12836.
35. Gelderman KA, Hultqvist M, Pizzolla A, Zhao M, Nandakumar KS, et al. (2007) Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species. J Clin Invest 117: 3020-3028.
36. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM (2009) Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 182: 2194-2202.
37. Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, et al. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 184: 1436-1444.
38. Nakamura K, Hori T, Sato N, Sugie K, Kawakami T, et al. (1993) Redox regulation of a src family protein tyrosine kinase p56lck in T cells. Oncogene 8: 3133-3139.
39. Hardwick JS, Sefton BM (1995) Activation of the Lck tyrosine protein kinase by hydrogen peroxide requires the phosphorylation of Tyr-394. Proc Natl Acad Sci U S A 92: 4527-4531.
40. Lee HM, Shin DM, Choi DK, Lee ZW, Kim KH, et al. (2009) Innate immune responses to Mycobacterium ulcerans via toll-like receptors and dectin-1 in human keratinocytes. Cell Microbiol 11: 678-692.
41. Laochumroonvorapong P, Paul S, Manca C, Freedman VH, Kaplan G (1997) Mycobacterial growth and sensitivity to H2O2 killing in human monocytes in vitro. Infect Immun 65: 4850-4857.
42. Manca C, Paul S, Barry CE, 3rd, Freedman VH, Kaplan G (1999) Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. Infect Immun 67: 74-79.
43. Subbian S, Mehta PK, Cirillo SL, Bermudez LE, Cirillo JD (2007) A Mycobacterium marinum mel2 mutant is defective for growth in macrophages that produce reactive oxygen and reactive nitrogen species. Infect Immun 75: 127-134.
44. Roberts B, Hirst R (1996) Identification and characterisation of a superoxide dismutase and catalase from Mycobacterium ulcerans. J Med Microbiol 45: 383-387.
45. Schäfer M, Werner S (2008) Oxidative stress in normal and impaired wound repair. Pharmacological Research 58: 165-171.
46. Vijayaraghavan R, Suribabu CS, Sekar B, Oommen PK, Kavithalakshmi SN, et al. (2005) Protective role of vitamin E on the oxidative stress in Hansen's disease (Leprosy) patients. Eur J Clin Nutr 59: 1121-1128.
47. Srinivasan S, Pragasam V, Jenita X, Kalaiselvi P, Muthu V, et al. (2004) Oxidative stress in urogenital tuberculosis patients: a predisposing factor for renal stone formation-amelioration by vitamin E supplementation. Clinica Chimica Acta 350: 57-63.
48. Cemerski S, Cantagrel A, van Meerwijk JPM, Romagnoli P (2002) Reactive Oxygen Species Differentially Affect T Cell Receptor-signaling Pathways*. J Biol Chem 277: 19585-19593.
49. Sinha A, Singh A, Satchidanandam V, Natarajan K (2006) Impaired Generation of Reactive Oxygen Species during Differentiation of Dendritic Cells (DCs) by Mycobacterium tuberculosis Secretory Antigen (MTSA) and Subsequent Activation of MTSA-DCs by Mycobacteria Results in Increased Intracellular Survival. J Immunol 177: 468-478.
50. Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M (2004) Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother 48: 2866-2870.
51. Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, et al. (2004) In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother 48: 3130-3132.
52. Zahrt TC, Deretic V (2002) Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid Redox Signal 4: 141-159.
53. Reddan J, Sevilla M, Giblin F, Padgaonkar V, Dziedzic D, et al. (1992) Tempol and deferoxamine protect cultured rabbit lens epithelial cells from H2O2 insult: insight into the mechanism of H2O2-induced injury. Lens Eye Toxic Res 9: 385-393.
54. Cronje L, Edmondson N, Eisenach KD, Bornman L (2005) Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocytemacrophage viability and effector functions. FEMS Immunol Med Microbiol 45: 103-112.
55. Gordeuk VR, Moyo VM, Nouraie M, Gangaidzo IT, Murphree NL, et al. (2009) Circulating cytokines in pulmonary tuberculosis according to HIV status and dietary iron content. Int J Tuberc Lung Dis 13: 1267-1273.
56. Gangaidzo IT, Moyo VM, Mvundura E, Aggrey G, Murphree NL, et al. (2001) Association of pulmonary tuberculosis with increased dietary iron. J Infect Dis 184: 936-939.
57. Hercberg S, Chauliac M, Galan P, Devanlay M, Zohoun I, et al. (1988) Prevalence of iron deficiency and iron-deficiency anaemia in Benin. Public Health 102: 73-83.
58. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, et al. (2003) Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 31: 299-304.
59. Gordeuk VR (2002) African iron overload. Seminars in Hematology 39: 263-269.
60. Van Zandt KE, Sow FB, Florence WC, Zwilling BS, Satoskar AR, et al. (2008) The iron export protein ferroportin 1 is differentially expressed in mouse macrophage populations and is present in the mycobacterial-containing phagosome. J Leukoc Biol 84: 689-700.
61. Stienstra Y, van der Werf TS, Oosterom E, Nolte IM, van der Graaf WT, et al. (2006) Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun 7: 185-189.